LABORATORY AND CLINICAL STUDIES ON CEFOPERAZONE (T-1551)

Abstract

On cefoperazone (CPZ, T-1551), a new cephalosporin derivative developed, in vitro antibacterial activities against gram-negative bacteria were compared with a variety of cephalosporins and cephamycins using clinical isolated bacteria including E. coli, E. cloacae, E. aero genes, K. pneumoniae, K. oxytoca, K. ozaenae, P. mirabilis, P. vulgaris, Serratia, P. aeruginosa and H. influenzae. CPZ was found to be more effective than CEZ, particularly against P. vulgaris, Serratia and P. aeruginosa.
CPZ was tested to the following infectious diseases and the following results were obtained. It was effective to 2 out of 3 cases of acute bronchitis, to 6 out of 7 cases of chronic bronchitis, to 13 cases of bacterial pneumonia, to 1 case of bronchiectasis, to 4 cases of pyothorax, to 3 out of 4 cases of acute pyelonephritis, to 5 out of 6 cases of chronic pyelonephritis, to 1 case of U.T.I., to 2 cases of acute cholecystitis and none of 2 cases of F.U.O. It was effective to 37 out of 43 cases in total and effective rate was 86.0%.
Classifying on the strains of causative organisms, it was effective to 1 case of S. aureus, to 9 of 11 cases of Pseudomonas, to 1 out of 2 cases of Klebsiella, to 5 out of 6 cases of E. coli, to 1 case of Citrobacter and to 1 case of Acinetobacter.
Side effects were noticed in total 4 cases consisting of 3 drug fever (1 with rash) and 1 case of elevation in serum transaminase and ALP (with eosinophilia). These values returned to normal immediately after the cessation of CPZ therapy.